Cargando…
T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization
BACKGROUND: We present a new family of ECG biomarkers for assessing drug effects on ventricular repolarization. We show that drugs blocking inward (depolarizing) ion currents cause a relative increase of the T vector velocity (TVV) and accelerate repolarization, while drugs blocking outward ion curr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613676/ https://www.ncbi.nlm.nih.gov/pubmed/31283756 http://dx.doi.org/10.1371/journal.pone.0204712 |
_version_ | 1783433072596746240 |
---|---|
author | Bystricky, Werner Maier, Christoph Gintant, Gary Bergau, Dennis Kamradt, Kent Welsh, Patrick Carter, David |
author_facet | Bystricky, Werner Maier, Christoph Gintant, Gary Bergau, Dennis Kamradt, Kent Welsh, Patrick Carter, David |
author_sort | Bystricky, Werner |
collection | PubMed |
description | BACKGROUND: We present a new family of ECG biomarkers for assessing drug effects on ventricular repolarization. We show that drugs blocking inward (depolarizing) ion currents cause a relative increase of the T vector velocity (TVV) and accelerate repolarization, while drugs blocking outward ion currents cause a relative decrease of the TVV and delay repolarization. The results suggest a link between the TVV and the instantaneous change of the cellular action potentials that may contribute to bridge the gap between the surface ECG and myocardial cellular processes. METHODS: We measure TVV as the time required to reach X% of the total Trajectory length of the T vector loop, denoted as TrX. Applied to data from two FDA funded studies (22+22 subjects, 5232+4208 ECGs) which target ECG effects of various ion-channel blocking drugs, the TrX effect profiles indicate increasingly delayed electrical activity over the entire repolarization process for drugs solely reducing outward potassium current (dofetilide, moxifloxacin). For drugs eliciting block of the inward sodium or calcium currents (mexiletine, lidocaine), the TrX effect profiles were consistent with accelerated electrical activity in the initial repolarization phase. For multichannel blocking drugs (ranolazine) or drug combinations blocking multiple ion currents (dofetilide + mexiletine, dofetilide + lidocaine), the overall TrX effect profiles indicate a superposition of the individual TrX effect profiles. RESULTS: The parameter Tr40c differentiates pure potassium channel blocking drugs from multichannel blocking drugs with an area under the ROC curve (AUC) of 0.90, CI = [0.88 to 0.92]. This is significantly better than the performance of J-T(peak)c (0.81, CI = [0.78 to 0.84]) identified as the best parameter in the second FDA study. Combining the ten parameters Tr10c to Tr100c in a logistic regression model further improved the AUC to 0.94, CI = [0.92 to 0.96]. CONCLUSIONS: TVV analysis substantially improves assessment of drug effects on cardiac repolarization, providing a plausible and improved mechanistic link between drug effects on ionic currents and overall ventricular repolarization reflected in the body surface ECG. TVV contributes to an enhanced appraisal of the proarrhythmic risk of drugs beyond QTc prolongation and J-T(peak)c. |
format | Online Article Text |
id | pubmed-6613676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-66136762019-07-23 T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization Bystricky, Werner Maier, Christoph Gintant, Gary Bergau, Dennis Kamradt, Kent Welsh, Patrick Carter, David PLoS One Research Article BACKGROUND: We present a new family of ECG biomarkers for assessing drug effects on ventricular repolarization. We show that drugs blocking inward (depolarizing) ion currents cause a relative increase of the T vector velocity (TVV) and accelerate repolarization, while drugs blocking outward ion currents cause a relative decrease of the TVV and delay repolarization. The results suggest a link between the TVV and the instantaneous change of the cellular action potentials that may contribute to bridge the gap between the surface ECG and myocardial cellular processes. METHODS: We measure TVV as the time required to reach X% of the total Trajectory length of the T vector loop, denoted as TrX. Applied to data from two FDA funded studies (22+22 subjects, 5232+4208 ECGs) which target ECG effects of various ion-channel blocking drugs, the TrX effect profiles indicate increasingly delayed electrical activity over the entire repolarization process for drugs solely reducing outward potassium current (dofetilide, moxifloxacin). For drugs eliciting block of the inward sodium or calcium currents (mexiletine, lidocaine), the TrX effect profiles were consistent with accelerated electrical activity in the initial repolarization phase. For multichannel blocking drugs (ranolazine) or drug combinations blocking multiple ion currents (dofetilide + mexiletine, dofetilide + lidocaine), the overall TrX effect profiles indicate a superposition of the individual TrX effect profiles. RESULTS: The parameter Tr40c differentiates pure potassium channel blocking drugs from multichannel blocking drugs with an area under the ROC curve (AUC) of 0.90, CI = [0.88 to 0.92]. This is significantly better than the performance of J-T(peak)c (0.81, CI = [0.78 to 0.84]) identified as the best parameter in the second FDA study. Combining the ten parameters Tr10c to Tr100c in a logistic regression model further improved the AUC to 0.94, CI = [0.92 to 0.96]. CONCLUSIONS: TVV analysis substantially improves assessment of drug effects on cardiac repolarization, providing a plausible and improved mechanistic link between drug effects on ionic currents and overall ventricular repolarization reflected in the body surface ECG. TVV contributes to an enhanced appraisal of the proarrhythmic risk of drugs beyond QTc prolongation and J-T(peak)c. Public Library of Science 2019-07-08 /pmc/articles/PMC6613676/ /pubmed/31283756 http://dx.doi.org/10.1371/journal.pone.0204712 Text en © 2019 Bystricky et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Bystricky, Werner Maier, Christoph Gintant, Gary Bergau, Dennis Kamradt, Kent Welsh, Patrick Carter, David T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization |
title | T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization |
title_full | T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization |
title_fullStr | T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization |
title_full_unstemmed | T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization |
title_short | T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization |
title_sort | t vector velocity: a new ecg biomarker for identifying drug effects on cardiac ventricular repolarization |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613676/ https://www.ncbi.nlm.nih.gov/pubmed/31283756 http://dx.doi.org/10.1371/journal.pone.0204712 |
work_keys_str_mv | AT bystrickywerner tvectorvelocityanewecgbiomarkerforidentifyingdrugeffectsoncardiacventricularrepolarization AT maierchristoph tvectorvelocityanewecgbiomarkerforidentifyingdrugeffectsoncardiacventricularrepolarization AT gintantgary tvectorvelocityanewecgbiomarkerforidentifyingdrugeffectsoncardiacventricularrepolarization AT bergaudennis tvectorvelocityanewecgbiomarkerforidentifyingdrugeffectsoncardiacventricularrepolarization AT kamradtkent tvectorvelocityanewecgbiomarkerforidentifyingdrugeffectsoncardiacventricularrepolarization AT welshpatrick tvectorvelocityanewecgbiomarkerforidentifyingdrugeffectsoncardiacventricularrepolarization AT carterdavid tvectorvelocityanewecgbiomarkerforidentifyingdrugeffectsoncardiacventricularrepolarization |